Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results
January 24, 2019 6:59 AM ESTIncreases Fourth Quarter Revenues 10% to $6.0 Billion, 9% for Full Year to $22.6 Billion Posts Fourth Quarter GAAP EPS of $0.73 and Non-GAAP EPS of $0.94 Announces Strategic Acquisition of Celgene Corporation Announces Voluntary Withdrawal of U.S. Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Lung Cancer in Patients with Tumor Mutational Burden 10 Mutations/Megabase, following discussions with the U.S. FDA Additional Opdivo Plus Yervoy Approvals in Europe for Patients with Renal Cell Carcinoma... More
